|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Janunger KG, Hafström L, Nygren P and
Glimelius B; SBU-group. Swedish Council of Technology Assessment in
Health Care: A systematic overview of chemotherapy effects in
gastric cancer. Acta Oncol. 40:309–326. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rojo F, Tabernero J, Albanell J, et al:
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from
patients with advanced gastric carcinoma. J Clin Oncol.
24:4309–4316. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moutinho C, Mateus AR, Milanezi F,
Carneiro F, Seruca R and Suriano G: Epidermal growth factor
receptor structural alterations in gastric cancer. BMC Cancer.
8:102008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Z, Liu L, Li M, et al: Epidermal
growth factor receptor mutation in gastric cancer. Pathology.
43:234–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rivera F, Vega-Villegas ME and López-Brea
MF: Cetuximab, its clinical use and future perspectives. Anticancer
Drugs. 19:99–113. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan JA, Blaszkowsky LS, Enzinger PC, et
al: A multicenter phase II trial of single-agent cetuximab in
advanced esophageal and gastric adenocarcinoma. Ann Oncol.
22:1367–1373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schoennemann KR, Bjerregaard JK, Hansen
TP, et al: Biweekly cetuximab and irinotecan as second-line therapy
in patients with gastro-esophageal cancer previously treated with
platinum. Gastric Cancer. 14:219–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi M, Ji J, Wu J, et al: Cetuximab
combined with FOLFOX4 as the first-line treatment for advanced
gastric cancer: report of 25 cases from a single institution.
Hepatogastroenterology. 59:1054–1058. 2012.PubMed/NCBI
|
|
12
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
et al: K-ras mutations and benefit from cetuximab in advanced
colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
De Roock W, Claes B, Bernasconi D, et al:
Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of
cetuximab plus chemotherapy in chemotherapy-refractory metastatic
colorectal cancer: a retrospective consortium analysis. Lancet
Oncol. 11:753–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sartore-Bianchi A, Di Nicolantonio F,
Nichelatti M, et al: Multi-determinants analysis of molecular
alterations for predicting clinical benefit to EGFR-targeted
monoclonal antibodies in colorectal cancer. PLoS One. 4:e72872009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Victor T, Du Toit R, Jordaan AM, Bester AJ
and van Helden PD: No evidence for point mutations in codons 12, 13
and 61 of the ras gene in a high-incidence area for esophageal and
gastric cancers. Cancer Res. 50:4911–4914. 1990.PubMed/NCBI
|
|
16
|
Hongyo T, Buzard GS, Palli D, et al:
Mutations of the K-ras and p53 genes in gastric adenocarcinomas
from a high-incidence region around Florence, Italy. Cancer Res.
55:2665–2672. 1995.PubMed/NCBI
|
|
17
|
Liu ZM, Liu LN, Li M, Zhang QP, Cheng SH
and Lu S: Mutation detection of KRAS by high-resolution melting
analysis in Chinese gastric cancer. Oncol Rep. 22:515–520.
2009.PubMed/NCBI
|
|
18
|
Corso G, Velho S, Paredes J, et al:
Oncogenic mutations in gastric cancer with microsatellite
instability. Eur J Cancer. 47:443–451. 2011. View Article : Google Scholar
|
|
19
|
Lee SH, Lee JW, Soung YH, et al: BRAF and
KRAS mutations in stomach cancer. Oncogene. 22:6942–6945. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim IJ, Park JH, Kang HC, et al:
Mutational analysis of BRAF and K-ras in gastric cancers: absence
of BRAF mutations in gastric cancers. Hum Genet. 114:118–120. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oliveira C, Pinto M, Duval A, et al: BRAF
mutations characterize colon but not gastric cancer with mismatch
repair deficiency. Oncogene. 22:9192–9196. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu M, Semba S, Oue N, Ikehara N, Yasui W
and Yokozaki H: BRAF/K-ras mutation, microsatellite instability and
promoter hypermethylation of hMLH1/MGMT in human gastric
carcinomas. Gastric Cancer. 7:246–253. 2004. View Article : Google Scholar
|
|
23
|
Zhao W, Chan TL, Chu KM, Chan AS, Stratton
MR, Yuen ST and Leung SY: Mutations of BRAF and KRAS in gastric
cancer and their association with microsatellite instability. Int J
Cancer. 108:167–169. 2004. View Article : Google Scholar
|
|
24
|
Sasao S, Hiyama T, Tanaka S, Yoshihara M,
Yasui W and Chayama K: Clinicopathologic and genetic
characteristics of gastric cancer in young male and female
patients. Oncol Rep. 16:11–15. 2006.PubMed/NCBI
|
|
25
|
Stella G, Rojas Llimpe F, Barone C, et al:
KRAS and BRAF mutational status as response biomarkers to cetuximab
combination therapy in advanced gastric cancer patients. ASCO Meet
Abstr. 27:e155032009.
|
|
26
|
Li VS, Wong CW, Chan TL, et al: Mutations
of PIK3CA in gastric adenocarcinoma. BMC Cancer. 5:292005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Samuels Y, Wang Z, Bardelli A, et al: High
frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Velho S, Oliveira C, Ferreira A, et al:
The prevalence of PIK3CA mutations in gastric and colon cancer. Eur
J Cancer. 41:1649–1654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bardelli A and Siena S: Molecular
mechanisms of resistance to cetuximab and panitumumab in colorectal
cancer. J Clin Oncol. 28:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kiaris H and Spandidos D: Mutations of ras
genes in human tumors (review). Int J Oncol. 7:413–421.
1995.PubMed/NCBI
|
|
31
|
van Grieken NC, Aoyama T, Chambers PA, et
al: KRAS and BRAF mutations are rare and related to DNA mismatch
repair deficiency in gastric cancer from the East and the West:
Results from a large international multicentre study. Br J Cancer.
108:1495–1501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Davies H, Bignell GR, Cox C, et al:
Mutations of the BRAF gene in human cancer. Nature. 417:949–954.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee SH, Ahn BK, Baek SU and Chang HK: BRAF
mutation in multiple primary cancer with colorectal cancer and
stomach cancer. Gastroenterol Rep (Oxf). 1:70–74. 2013. View Article : Google Scholar
|
|
34
|
Henke LE, Perkins SM, Pfeifer JD, Ma C,
Chen Y, DeWees T and Grigsby PW: BRAF V600E mutational status in
pediatric thyroid cancer. Pediatr Blood Cancer. 61:1168–1172. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Campbell IG, Russell SE, Choong DY, et al:
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer
Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee JW, Soung YH, Kim SY, et al: PIK3CA
gene is frequently mutated in breast carcinomas and hepatocellular
carcinomas. Oncogene. 24:1477–1480. 2005. View Article : Google Scholar
|
|
37
|
Simi L, Pratesi N, Vignoli M, et al:
High-resolution melting analysis for rapid detection of KRAS, BRAF
and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol.
130:247–253. 2008. View Article : Google Scholar : PubMed/NCBI
|
